Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Total Liabilities & Equity
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Z
|
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
|
Total Liabilities & Equity
¥10.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
17%
|
CAGR 10-Years
15%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Liabilities & Equity
¥39.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Liabilities & Equity
¥69.9B
|
CAGR 3-Years
18%
|
CAGR 5-Years
15%
|
CAGR 10-Years
20%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Total Liabilities & Equity
¥54.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
11%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Total Liabilities & Equity
¥45.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Liabilities & Equity
¥7.1B
|
CAGR 3-Years
96%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Glance View
Founded in 1973, Zhejiang Jiuzhou Pharmaceutical Co. Ltd. has steadily navigated the evolving tides of the global pharmaceutical industry with a compelling blend of innovation and traditional business acumen. Rooted in China's dynamic Zhejiang province, the company initially focused on manufacturing basic pharmaceutical intermediates. Over the years, it strategically expanded its operations, becoming a key player in both the Active Pharmaceutical Ingredients (APIs) and Contract Development and Manufacturing Organization (CDMO) sectors. This dual focus has allowed Jiuzhou Pharmaceutical to innovate and offer comprehensive services, ranging from drug development to commercial manufacturing, effectively appealing to a broad range of customers including some of the world's leading pharmaceutical companies. At the heart of Jiuzhou Pharmaceutical's success lies its commitment to research and development, a cornerstone that supports its diversification strategy. The company leverages its extensive expertise and cutting-edge technology to improve existing drugs while also participating in the development of new, patented pharmaceuticals. By fostering strong partnerships with global pharmaceutical giants, Jiuzhou effectively integrates itself into the larger pharmaceutical ecosystem, providing customized solutions that resonate with market demand. This business model not only reinforces its financial growth but also establishes Zhejiang Jiuzhou as an indispensable contributor to advancements in medicine, continually enhancing its reputation on the international stage.
See Also
What is Zhejiang Jiuzhou Pharmaceutical Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
10.7B
CNY
Based on the financial report for Sep 30, 2025, Zhejiang Jiuzhou Pharmaceutical Co Ltd's Total Liabilities & Equity amounts to 10.7B CNY.
What is Zhejiang Jiuzhou Pharmaceutical Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
15%
Over the last year, the Total Liabilities & Equity growth was -3%. The average annual Total Liabilities & Equity growth rates for Zhejiang Jiuzhou Pharmaceutical Co Ltd have been 11% over the past three years , 17% over the past five years , and 15% over the past ten years .